A novel mouse model of atopic dermatitis with epicutaneous allergen sensitization and the effect of Lactobacillus rhamnosus

Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease, and the pathogenesis is not completely understood. Although there are some mouse models of AD, it is not easy to establish model to represent the natural AD development in human. In this study, we developed an AD model base...

Full description

Saved in:
Bibliographic Details
Published inExperimental dermatology Vol. 21; no. 9; pp. 672 - 675
Main Authors Kim, Ha-Jung, Kim, Young-Joon, Kang, Mi-Jin, Seo, Ju-Hee, Kim, Hyung-Young, Jeong, Se Kyoo, Lee, Seung-Hun, Kim, Ji-Min, Hong, Soo-Jong
Format Journal Article
LanguageEnglish
Published Oxford Blackwell Publishing Ltd 01.09.2012
Blackwell
Subjects
Online AccessGet full text
ISSN0906-6705
1600-0625
1600-0625
DOI10.1111/j.1600-0625.2012.01539.x

Cover

More Information
Summary:Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease, and the pathogenesis is not completely understood. Although there are some mouse models of AD, it is not easy to establish model to represent the natural AD development in human. In this study, we developed an AD model based on outside–inside theory and investigated the effect of Lactobacillus rhamnosus (Lcr35), which have known as an immune modulator in allergic diseases. SKH‐1 hairless mice underwent three 1‐week exposures (separated by 2‐week intervals) to an ovalbumin (OVA) or saline (control) patch at the same site to develop the mouse model of AD. Lcr35 (1 × 109 CFU) was administered orally every day from 1 week before the first sensitization until the end of the study. The AD model induced erythematous and itchy skin, increasing TEWL and increasing skin inflammation as assessed by histology in the mice. Oral Lcr35 attenuated all disease parameters previously mentioned. OVA‐specific IgE and skin expression of interleukin‐4 (IL‐4) and thymic stromal lymphopoietin (TSLP) increased in AD mice, but were reduced in AD mice treated with Lcr35. Moreover, Lcr35 treatment led to an increase in CD4+CD25+ Foxp3+ Treg cells in the mesenteric lymph nodes of AD mice. In conclusions, based on the ‘outside–inside’ theory, topical allergen may induce AD without skin injury. Oral application of Lcr35 prevented the development of AD in this model by suppressing production of the inflammatory cytokines, IL‐4 and TSLP in the skin via a mechanism that may involve CD4+CD25+Foxp3+Treg cells.
Bibliography:ArticleID:EXD1539
Korea government (MEST) - No. 2010-0022233
National Research Foundation of Korea
istex:D193D364CF66AEBB149FE36E27978A4B32FDF287
ark:/67375/WNG-KG2P1FQJ-G
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0906-6705
1600-0625
1600-0625
DOI:10.1111/j.1600-0625.2012.01539.x